Blog
RSS FeedPosted by Michael Wonder on 06 Jan 2026
NICE recommends new treatment option for highly active multiple sclerosis
2 January 2026 - Thousands of people living with a form of multiple sclerosis will benefit from greater treatment choice, following ...
Posted by Michael Wonder on 24 Dec 2025
Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
24 December 2025 - More than 7,000 people in England will now be able to access to a life-extending treatment for ...
Posted by Michael Wonder on 01 Dec 2025
Changes to NICE’s cost effectiveness thresholds confirmed
1 December 2025 - The Government has today announced that it will increase the thresholds NICE uses in evaluations of new ...
Posted by Michael Wonder on 26 Nov 2025
Hundreds could benefit from life saving blood cancer treatment recommended by NICE
25 November 2025 - People with a rare and aggressive blood cancer will benefit from a potentially life saving treatment, following ...
Posted by Michael Wonder on 21 Nov 2025
Alnylam's ATTR cardiomyopathy drug backed for NHS use
21 November 2025 - Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be ...
Posted by Michael Wonder on 31 Oct 2025
NICE’s backing of the prostate cancer drug abiraterone could help thousands and save the NHS millions
30 October 2025 - Today we’ve published final draft guidance recommending abiraterone and its generic variants in combination with androgen ...
Posted by Michael Wonder on 24 Oct 2025
Up to 6,000 patients to benefit from NICE-approved life-extending prostate cancer drug
24 October 2025 - People living with metastatic prostate cancer in England will gain access to a new treatment combination from ...
Posted by Michael Wonder on 22 Oct 2025
Sarilumab for the treatment of children/adolescents 2-17 years of age with polyarticular or oligoarticular juvenile idiopathic arthritis
22 October 2025 - NICE is unable to make a recommendation on the use of sarilumab (Kevzara) for the treatment of ...
Posted by Michael Wonder on 22 Oct 2025
Clascoterone for the treatment of patients 12 years of age and older with acne vulgaris
22 October 2025 - NICE is unable to make a recommendation on the use of clascoterone (Winlevi) for the treatment of patients ...
Posted by Michael Wonder on 17 Oct 2025
First HIV prevention injection for people unable to have daily PrEP recommended
17 October 2025 - A ground-breaking HIV-1 prevention injection has been recommended by NICE, marking a significant advance for a small ...
Posted by Michael Wonder on 17 Oct 2025
Same time decisions on licensing and value - what pharmaceutical companies need to know
10 October 2025 - Learn how NICE and MHRA are launching an aligned pathway to accelerate patient access to medicines and ...
Posted by Michael Wonder on 11 Oct 2025
MHRA and NICE invite early adopters to trial accelerated aligned pathway – six months ahead of schedule
10 October 2025 - Aligned pathway will streamline decisions on licensing and value for medicines, helping patients to benefit from them ...
Posted by Michael Wonder on 17 Sep 2025
Hundreds of people set to benefit after life-extending lung cancer treatment given green light
16 September 2025 - Targeted immunotherapy found to significantly increase overall survival rates for people with an aggressive form of lung ...
Posted by Michael Wonder on 11 Sep 2025
Methods used in early value assessments for NICE: a scoping review
8 September 2025 - NICE in England introduced early value assessments as an evidence-based method of accelerating access to promising ...
Posted by Michael Wonder on 22 Aug 2025
Breakthrough life-extending combination treatment for advanced bladder cancer recommended by NICE
21 August 2025 - NICE has recommended a new first-line treatment for adults with advanced bladder cancer, marking a significant ...